What can molecular pathology contribute to the management of renal cell carcinoma?

@article{Stewart2011WhatCM,
  title={What can molecular pathology contribute to the management of renal cell carcinoma?},
  author={Grant S Stewart and Fiach C. O'Mahony and Thomas Powles and Antony C. P. Riddick and David J. Harrison and Dana Faratian},
  journal={Nature Reviews Urology},
  year={2011},
  volume={8},
  pages={255-265}
}
The incidence of renal cell carcinoma (RCC) is increasing and outcomes remain poor. One-third of patients with localized disease will relapse, and 5-year survival for patients with metastatic disease is less than 10%. No molecular test is currently available to identify which patients who have undergone 'curative' surgery will relapse, and which patients will respond to targeted therapy. Some well characterized biochemical pathways, such as those associated with von Hippel–Lindau disease, are… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 114 references

Cancer statistics , 2010

E. Ward
CA Cancer J . Clin . • 2011

Future of personalized medicine in oncology: a systems biology approach.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2010

Similar Papers

Loading similar papers…